Zydus gets USFDA nod to market Fingolimod capsules for sclerosis

Drug firm Zydus Cadila today said it has received tentative nod from the US health regulator to market Fingolimod capsules used for treatment of multiple sclerosis.

"The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Fingolimod capsules 0.5 mg," Cadila Healthcare said in a filing to BSE.

The drug will be produced at the group's formulations manufacturing facility at pharma SEZ in Ahmedabad, it added.

The product is mainly used for treating multiple sclerosis, Cadila said.

The group now has over 120 approvals and has so far filed more than 300 Abbreviated New Drug Applications (ANDAs), it added.

Shares of Cadila Healthcare today closed at Rs 532.50 per scrip on BSE, up 2.68 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel